| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YGYNO.2005.10.029 |
| P698 | PubMed publication ID | 16360201 |
| P50 | author | Mef Nilbert | Q42752494 |
| P2093 | author name string | Ake Borg | |
| Ulf Kristoffersson | |||
| Susanne Malander | |||
| Mona Ridderheim | |||
| Britta Halvarsson | |||
| Eva Rambech | |||
| P2860 | cites work | DNA replication errors are frequent in mucinous cystadenocarcinoma of the ovary | Q73506437 |
| Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences | Q73526242 | ||
| p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang | Q73752688 | ||
| A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers | Q74519444 | ||
| BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing | Q74525381 | ||
| One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden | Q75344773 | ||
| Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours | Q78852509 | ||
| Different types of microsatellite instability in ovarian carcinoma | Q80594382 | ||
| Familial endometrial cancer in female carriers of MSH6 germline mutations | Q28145436 | ||
| MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas | Q28288475 | ||
| Tissue microarrays for high-throughput molecular profiling of tumor specimens | Q29618675 | ||
| Cancer statistics, 2000. | Q33895772 | ||
| Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer | Q34113283 | ||
| Cancer risk in mutation carriers of DNA-mismatch-repair genes | Q34502900 | ||
| Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGE review | Q34990750 | ||
| Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors | Q35748966 | ||
| Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database | Q35940640 | ||
| Microsatellite instability in ovarian neoplasms | Q36081495 | ||
| Hereditary ovarian cancer. | Q36235943 | ||
| Microsatellite instability differences between familial and sporadic ovarian cancers | Q38353435 | ||
| DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells | Q40679888 | ||
| Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine | Q44356046 | ||
| Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. | Q44644581 | ||
| Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma | Q47616503 | ||
| Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients | Q47927589 | ||
| Gynecologic screening in hereditary nonpolyposis colorectal cancer | Q50731723 | ||
| The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. | Q53322529 | ||
| New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. | Q55033068 | ||
| Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer | Q57567891 | ||
| Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer? | Q57741879 | ||
| Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome. | Q60458159 | ||
| Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. | Q64964658 | ||
| Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer | Q70870193 | ||
| P433 | issue | 2 | |
| P921 | main subject | ovarian cancer | Q172341 |
| colorectal cancer | Q188874 | ||
| Lynch syndrome | Q783644 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 238-243 | |
| P577 | publication date | 2005-12-19 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer | |
| P478 | volume | 101 |
| Q28283356 | A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer |
| Q34088809 | Application of molecular diagnostics for the detection of Lynch syndrome |
| Q34910918 | Cancer Genetics: Risks and Mechanisms of Cancer in Women with Inherited Susceptibility to Epithelial Ovarian Cancer |
| Q64130128 | Characteristics and survival associated with ovarian cancer diagnosed as first cancer and ovarian cancer diagnosed subsequent to a previous cancer |
| Q30491616 | Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response |
| Q83131182 | Consideration of hereditary nonpolyposis colorectal cancer in BRCA mutation-negative familial ovarian cancers |
| Q59272586 | Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas |
| Q88235295 | Disparities in genetics assessment for women with ovarian cancer: Can we do better? |
| Q34507528 | Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome |
| Q36059087 | Do hereditary syndrome-related gynecologic cancers have any specific features? |
| Q47140496 | Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations. |
| Q41352646 | Expression of cancer related BRCA1 missense variants decreases MMS-induced recombination in Saccharomyces cerevisiae without altering its nuclear localization |
| Q57815823 | Familial risks of second primary cancers and mortality in ovarian cancer patients |
| Q34265940 | Features of ovarian cancer in Lynch syndrome (Review). |
| Q35023943 | Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America |
| Q36385676 | Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer |
| Q92552733 | Genetic counseling of patients with ovarian carcinoma: acceptance, timing, and psychological wellbeing |
| Q36108520 | Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic |
| Q37472467 | Genetic testing in a gynaecological oncology care in developing countries-knowledge, attitudes and perception of Nepalese clinicians |
| Q57471064 | Germline pathogenic variants identified in women with ovarian tumors |
| Q34977063 | Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management |
| Q88353828 | Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer |
| Q36130577 | Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system |
| Q35821477 | Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary |
| Q38426073 | Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population. |
| Q35872796 | Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy |
| Q38170877 | Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications |
| Q52678656 | Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer. |
| Q37967486 | Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form. |
| Q37293672 | Molecular pathogenesis of endometrial and ovarian cancer |
| Q28249514 | Mutations in BRIP1 confer high risk of ovarian cancer |
| Q89880356 | Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells |
| Q83572257 | Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors |
| Q34692155 | Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1 |
| Q91773365 | PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer |
| Q37693658 | Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer. |
| Q43625600 | Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry |
| Q37147224 | Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer |
| Q36243394 | Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival |
| Q37128242 | Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology |
| Q33991747 | The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population |
| Q34081267 | The genetic basis of Lynch syndrome and its implications for clinical practice and risk management |
| Q34775177 | The inherited genetics of ovarian and endometrial cancer |
| Q37572252 | Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer. |
Search more.